CeriBell, Inc.
HealthcareNASDAQ:CBLL · NASDAQ Global Select
+$0.32 today
Vol 0.20M · Avg 0.30M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-34.4%
avg 3.4%
ROIC
-32.9%
avg -39.2%
ROA
-27.3%
avg -34.6%
Analysis
ROA is currently the strongest return metric at -27.3% versus its period average of -34.6%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Xingjuan Chao | Co-Founder, President, Chief Executive Officer & Director | $1.28M | — | 45 | $839,871.00 | 2.21% |
Scott Blumberg | Chief Financial Officer | $677,065.00 | — | — | $147,683.00 | 0.39% |
Raymond Woo | Chief Technology Officer | $657,085.00 | — | 43 | $195,682.00 | 0.52% |
Josef Parvizi | Co-Founder, Chief Medical Advisor & Director | $242,525.00 | — | 57 | $23,284.00 | 0.06% |
David Foehr | Senior Vice President of Finance | — | — | — | $37,751.00 | 0.10% |
Brian Price | Senior Vice President of Marketing | — | — | — | — | — |
Dan Rogy | Senior Vice President of Operations | — | — | — | — | — |
Joseph S. Manni | Chief Revenue Officer | — | — | 52 | $67,073.00 | 0.18% |
Baharan Kamousi | Senior Vice President of Data Science | — | — | — | — | — |
Kim McKeon | Vice President of People & Culture | — | — | — | — | — |
Louisa Daniels | General Counsel | — | — | 68 | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
1
$55,236.50
Sells
58
$10.88M
Net Sentiment
$10.82M
Net selling
Most Active
Woo Raymond
20 transactions
1–10 of 59
Analysis
Insiders reported 1 buys worth $55,236.50 and 58 sells worth $10.88M over the last 12 months. That adds up to net selling of $10.82M. Woo Raymond was the most active insider with 20 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A2 analysts |
| Revenue | N/A | N/A | +50.9% | +25.6% (5yr)3 analysts |
| Net Income | N/A | N/A | N/A | N/A3 analysts |
| EBIT | N/A | N/A | N/A | N/A3 analysts |
Analysis
Recent growth has been strongest in Revenue at +50.9% over three years. Forward estimates point to Revenue at +25.6% (5yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Butterfly Network, Inc.
NYSE:BFLY
$1.45B
Enhabit, Inc.
EHAB
$706.91M
Surmodics, Inc.
SRDX
$614.51M
Varex Imaging Corporation
NASDAQ:VREX
$464.78M
OrthoPediatrics Corp.
NASDAQ:KIDS
$457.71M
Autolus Therapeutics plc
NASDAQ:AUTL
$415.18M
Standard BioTools Inc.
NASDAQ:LAB
$346.53M
Semler Scientific, Inc.
SMLR
$310.75M
Treace Medical Concepts, Inc.
NASDAQ:TMCI
$263.38M
Quantum-Si incorporated
NASDAQ:QSI
$187.28M
Who manages CBLL?
CeriBell, Inc. (CBLL) lists 11 active executives. The top listed executive is David Foehr, Senior Vice President of Finance.
Are CBLL insiders buying or selling?
Recent insider activity shows net selling of $4.36M.
Explore More
Continue the stock analysis
Jump to another research area for this company.